The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Therapy-Induced Acute Recruitment of Circulating Endothelial Progenitor Cells to Tumors
Abstract
The contribution of bone marrow–derived circulating endothelial progenitor cells (CEPs) to tumor angiogenesis has been controversial, primarily because of their low numbers in blood vessels of untreated tumors. We show that treatment of tumor-bearing mice with vascular disrupting agents (VDAs) leads to an acute mobilization of CEPs, which home to the viable tumor rim that characteristically remains after such therapy. Disruption of this CEP spike by antiangiogenic drugs or by genetic manipulation resulted in marked reductions in tumor rim size and blood flow as well as enhanced VDA antitumor activity. These findings also provide a mechanistic rationale for the enhanced efficacy of VDAs when combined with antiangiogenic drugs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Isolation of Putative Progenitor Endothelial Cells for Angiogenesis
Asahara, T., Murohara, T., Sullivan, A., Silver, M., van der Zee, R., Li, T., Witzenbichler, B., Schatteman, G., & Isner, J. M. (1997) · Science · doi:10.1126/science.275.5302.964 · Cited by 8,725
Endothelial Progenitor Cells: Characterization and Role in Vascular Biology
Urbich, C., & Dimmeler, S. (2004) · Circulation Research · doi:10.1161/01.res.0000137877.89448.78 · Cited by 2,369
Lyden, D., Hattori, K., Dias, S., Costa, C., Blaikie, P., Butros, L., Chadburn, A., Heissig, B., Marks, W., Witte, L., et al. (2001) · Nature Medicine · doi:10.1038/nm1101-1194 · Cited by 1,860
Self-citationDe Palma, M., Venneri, M. A., Galli, R., Sergi, L. S., Politi, L. S., Sampaolesi, M., & Naldini, L. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.08.002 · Cited by 1,311
VEGF-Induced Adult Neovascularization: Recruitment, Retention, and Role of Accessory Cells
Grunewald, M., Avraham, I., Dor, Y., Bachar-Lustig, E., Itin, A., Yung, S., Chimenti, S., Landsman, L., Abramovitch, R., & Keshet, E. (2006) · Cell · doi:10.1016/j.cell.2005.10.036 · Cited by 1,126
Disrupting tumour blood vessels
Tozer, G. M., Kanthou, C., & Baguley, B. C. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1628 · Cited by 930
Id1 and Id3 are required for neurogenesis, angiogenesis and vascularization of tumour xenografts
Lyden, D., Young, A. Z., Zagzag, D., Yan, W., Gerald, W., O'Reilly, R., Bader, B. L., Hynes, R. O., Zhuang, Y., Manova, K., et al. (1999) · Nature · doi:10.1038/44334 · Cited by 922
Self-citationPrewett, M. C., Huber, J., Li, Y., Santiago, A., O'Connor, W., King, K. D., Overholser, J. C., Hooper, A. T., Pytowski, B., Witte, L., et al. (1999) · PubMed · Cited by 713
Self-citationVascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy?
Rafii, S., Lyden, D., Benezra, R., Hattori, K., & Heissig, B. (2002) · Nature Reviews Cancer · doi:10.1038/nrc925 · Cited by 679
Self-citationContribution of bone marrow–derived endothelial cells to human tumor vasculature
Peters, B. A., Diaz, L. A., Polyak, K., Meszler, L., Romans, K., Guinan, E. C., Antin, J. H., Myerson, D., Hamilton, S. R., Vogelstein, B., et al. (2005) · Nature Medicine · doi:10.1038/nm1200 · Cited by 482
Cited by
Microenvironmental regulation of metastasis
Joyce, J. A., & Pollard, J. W. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2618 · Cited by 3,684
“Resistance to these drugs can be overcome in part through anti-VEGFR2 blocking antibodies, or by genetic ablation of EPCs in ID1 and ID3-deficient mic”
BackgroundModes of resistance to anti-angiogenic therapy
Bergers, G., & Hanahan, D. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2442 · Cited by 2,953
Kerbel, R. S. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0706596 · Cited by 1,948
Self-citationTumor angiogenesis: molecular pathways and therapeutic targets
Weis, S. M., & Cheresh, D. A. (2011) · Nature Medicine · doi:10.1038/nm.2537 · Cited by 1,736
The tumour-induced systemic environment as a critical regulator of cancer progression and metastasis
McAllister, S. S., & Weinberg, R. A. (2014) · Nature Cell Biology · doi:10.1038/ncb3015 · Cited by 966
Antiangiogenic therapy in oncology: current status and future directions
Jayson, G. C., Kerbel, R., Ellis, L. M., & Harris, A. L. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01088-0 · Cited by 828
Self-citationAnti-angiogenic therapy for cancer: current progress, unresolved questions and future directions
Vasudev, N. S., & Reynolds, A. R. (2014) · Angiogenesis · doi:10.1007/s10456-014-9420-y · Cited by 738
(2016) · ecancermedicalscience · doi:10.3332/ecancer.2014.463 · Cited by 676
Butler, J. M., Kobayashi, H., & Rafii, S. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2791 · Cited by 578
The multifaceted circulating endothelial cell in cancer: towards marker and target identification
Bertolini, F., Shaked, Y., Mancuso, P., & Kerbel, R. S. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1971 · Cited by 575
Self-citationFLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy?
Fischer, C., Mazzone, M., Jonckx, B., & Carmeliet, P. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2524 · Cited by 568
Roles for Growth Factors in Cancer Progression
Witsch, E., Sela, M., & Yarden, Y. (2010) · Physiology · doi:10.1152/physiol.00045.2009 · Cited by 526
Endothelial progenitor cells: identity defined?
Timmermans, F., Plum, J., Yöder, M. C., Ingram, D. A., Vandekerckhove, B., & Case, J. (2009) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2008.00598.x · Cited by 497
Neoadjuvant chemotherapy induces breast cancer metastasis through a TMEM-mediated mechanism
Karagiannis, G. S., Pastoriza, J. M., Wang, Y., Harney, A. S., Entenberg, D., Pignatelli, J., Sharma, V. P., Xue, E. A., Cheng, E., D’Alfonso, T. M., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aan0026 · Cited by 497
Beyond chemotherapy: targeted therapies in ovarian cancer
Yap, T. A., Carden, C. P., & Kaye, S. B. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2583 · Cited by 495
Adipose tissue angiogenesis as a therapeutic target for obesity and metabolic diseases
Cao, Y. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3055 · Cited by 442
Shaked, Y., Henke, E., Roodhart, J. M. L., Mancuso, P., Langenberg, M. H. G., Colleoni, M., Daenen, L. G., Man, S., Xu, P., Emmenegger, U., et al. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.08.001 · Cited by 440
Self-citationAhn, G.-O., & Brown, J. M. (2008) · Cancer Cell · doi:10.1016/j.ccr.2007.11.032 · Cited by 432
Purhonen, S., Palm, J., Rossi, D., Kaskenpää, N., Rajantie, I., Ylä-Herttuala, S., Alitalo, K., Weissman, I. L., & Salven, P. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0710516105 · Cited by 399
Human Endothelial Progenitor Cells
Yoder, M. C. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006692 · Cited by 397
Nolan, D. J., Ciarrocchi, A., Mellick, A. S., Jaggi, J. S., Bambino, K., Gupta, S., Heikamp, E., McDevitt, M. R., Scheinberg, D. A., Benezra, R., et al. (2007) · Genes & Development · doi:10.1101/gad.436307 · Cited by 394
Self-citationFolkins, C., Shaked, Y., Man, S., Tang, T., Lee, C. R., Zhu, Z., Hoffman, R. M., & Kerbel, R. S. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0167 · Cited by 374
Self-citationCombination of antiangiogenesis with chemotherapy for more effective cancer treatment
Ma, J., & Waxman, D. J. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0715 · Cited by 370
Lotti, F., Jarrar, A. M., Pai, R. K., Hitomi, M., Lathia, J., Mace, A., Gantt, G. A., Sukhdeo, K., DeVecchio, J., Vasanji, A., et al. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20131195 · Cited by 359
Zhang, Y., Daquinag, A., Traktuev, D. O., Amaya-Manzanares, F., Simmons, P. J., March, K. L., Pasqualini, R., Arap, W., & Kolonin, M. G. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3444 · Cited by 331
Metronomics: towards personalized chemotherapy?
André, N., Carré, M., & Pasquier, E. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.89 · Cited by 320
Pathways mediating VEGF-independent tumor angiogenesis
Ferrara, N. (2010) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2009.11.003 · Cited by 313
In vivo preclinical photoacoustic imaging of tumor vasculature development and therapy
Laufer, J. G., Zhang, E. Z., Treeby, B. E., Cox, B. T., Beard, P. C., Johnson, P., & Pedley, B. (2012) · Journal of Biomedical Optics · doi:10.1117/1.jbo.17.5.056016 · Cited by 308
The renin-angiotensin system and malignancy
Ager, E. I., Neo, J., & Christophi, C. (2008) · Carcinogenesis · doi:10.1093/carcin/bgn171 · Cited by 295
Positive and Negative Modulation of Angiogenesis by VEGFR1 Ligands
Cao, Y. (2009) · Science Signaling · doi:10.1126/scisignal.259re1 · Cited by 289
Tie2-expressing monocytes: regulation of tumor angiogenesis and therapeutic implications
De Palma, M., Murdoch, C., Venneri, M. A., Naldini, L., & Lewis, C. E. (2007) · Trends in Immunology · doi:10.1016/j.it.2007.09.004 · Cited by 287
Kozin, S. V., Kamoun, W. S., Huang, Y., Dawson, M. R., Jain, R. K., & Duda, D. G. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-4446 · Cited by 277
Loges, S., Schmidt, T., & Carmeliet, P. (2010) · Genes & Cancer · doi:10.1177/1947601909356574 · Cited by 257
El‐Kenawi, A. E., & El‐Remessy, A. B. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12344 · Cited by 253
Role of vascular normalization in benefit from metronomic chemotherapy
Mpekris, F., Baish, J. W., Stylianopoulos, T., & Jain, R. K. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1700340114 · Cited by 178
Rapisarda, A., Hollingshead, M., Uranchimeg, B., Bonomi, C. A., Borgel, S. D., Carter, J. P., Gehrs, B., Raffeld, M., Kinders, R. J., Parchment, R., et al. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0274 · Cited by 171
Tumour endothelial cells acquire drug resistance in a tumour microenvironment
Hida, K., Akiyama, K., Ohga, N., Maishi, N., & Hida, Y. (2013) · Journal of Biochemistry · doi:10.1093/jb/mvs152 · Cited by 68
Host effects contributing to cancer therapy resistance.
Katz, O. B., & Shaked, Y. (2015) · Drug Resistance Updates · doi:10.1016/j.drup.2014.12.002 · Cited by 47
Self-citationRecent concepts of antiangiogenic therapy
Konno, H., Yamamoto, M., & Ohta, M. (2010) · Surgery Today · doi:10.1007/s00595-009-4150-2 · Cited by 16
Metadata
- Authors
- Shaked, Y., Ciarrocchi, A., Franco, M., Lee, C. R., Man, S., Cheung, A. M., Hicklin, D. J., Chaplin, D., Foster, F. S., Benezra, R., & Kerbel, R. S.
- Venue
- Science
- Published
- 2006-09-22
- Volume
- 313
- Issue
- 5794
- Pages
- 1785-1787
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2098282622
- Cited by
- 570
- References
- 19
- FWCI
- 20.51
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.